HMGN1 protein regulates poly(ADP-ribose) polymerase-1 (PARP-1) self-PARylation in mouse fibroblasts. 2012

Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
Laboratory of Structural Biology, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709-2233, USA.

In mammalian cells, the nucleosome-binding protein HMGN1 (high mobility group N1) affects the structure and function of chromatin and plays a role in repair of damaged DNA. HMGN1 affects the interaction of DNA repair factors with chromatin and their access to damaged DNA; however, not all of the repair factors affected have been identified. Here, we report that HMGN1 affects the self-poly(ADP-ribosyl)ation (i.e., PARylation) of poly(ADP-ribose) polymerase-1 (PARP-1), a multifunctional and abundant nuclear enzyme known to recognize DNA lesions and promote chromatin remodeling, DNA repair, and other nucleic acid transactions. The catalytic activity of PARP-1 is activated by DNA with a strand break, and this results in self-PARylation and PARylation of other chromatin proteins. Using cells obtained from Hmgn1(-/-) and Hmgn1(+/+) littermate mice, we find that in untreated cells, loss of HMGN1 protein reduces PARP-1 self-PARylation. A similar result was obtained after MMS treatment of these cells. In imaging experiments after low energy laser-induced DNA damage, less PARylation at lesion sites was observed in Hmgn1(-/-) than in Hmgn1(+/+) cells. The HMGN1 regulation of PARP-1 activity could be mediated by direct protein-protein interaction as HMGN1 and PARP-1 were found to interact in binding assays. Purified HMGN1 was able to stimulate self-PARylation of purified PARP-1, and in experiments with cell extracts, self-PARylation was greater in Hmgn1(+/+) than in Hmgn1(-/-) extract. The results suggest a regulatory role for HMGN1 in PARP-1 activation.

UI MeSH Term Description Entries
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000071137 Poly (ADP-Ribose) Polymerase-1 A poly(ADP-ribose) polymerase that contains two ZINC FINGERS in its N-terminal DNA-binding region. It modifies NUCLEAR PROTEINS involved in chromatin architecture and BASE EXCISION REPAIR with POLY ADENOSINE DIPHOSPHATE RIBOSE. NAD+ ADP-ribosyltransferase-1,PARP-1 Protein,PARP1 Protein,Poly (ADP-Ribose) Synthase-1,NAD+ ADP ribosyltransferase 1,PARP 1 Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D042002 Chromatin Assembly and Disassembly The mechanisms effecting establishment, maintenance, and modification of that specific physical conformation of CHROMATIN determining the transcriptional accessibility or inaccessibility of the DNA. Chromatin Remodeling,Chromatin Assembly,Chromatin Disassembly,Chromatin Modeling,Chromatin Disassemblies,Disassembly, Chromatin,Remodeling, Chromatin
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053904 DNA Breaks, Single-Stranded Interruptions in one of the strands of the sugar-phosphate backbone of double-stranded DNA. Single-Stranded DNA Breaks,DNA Nicks,Single-Strand DNA Breaks,Single-Stranded DNA Break,Break, Single-Strand DNA,Break, Single-Stranded DNA,Breaks, Single-Strand DNA,Breaks, Single-Stranded DNA,DNA Break, Single-Strand,DNA Break, Single-Stranded,DNA Breaks, Single Stranded,DNA Breaks, Single-Strand,DNA Nick,Nick, DNA,Nicks, DNA,Single Strand DNA Breaks,Single Stranded DNA Break,Single Stranded DNA Breaks,Single-Strand DNA Break

Related Publications

Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
November 2018, Hypertension (Dallas, Tex. : 1979),
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
January 2012, PLoS genetics,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
February 2003, Journal of immunology (Baltimore, Md. : 1950),
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
November 2012, Nihon rinsho. Japanese journal of clinical medicine,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
December 2011, Endocrine, metabolic & immune disorders drug targets,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
July 2019, Biology of the cell,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
January 2006, Recent patents on anti-cancer drug discovery,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
February 2008, Current opinion in pharmacology,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
January 2010, Vascular pharmacology,
Aya Masaoka, and Natalie R Gassman, and Padmini S Kedar, and Rajendra Prasad, and Esther W Hou, and Julie K Horton, and Michael Bustin, and Samuel H Wilson
September 2007, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!